1 healthcare stock for long-term investors and 2 we ignore

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 31.5% over the past six months while the S&P 500 was up 6.8%.

Although these businesses have produced results, only a handful will thrive over the long term as the influx of venture capital has ushered in a new wave of competition. Keeping that in mind, here is one healthcare stock poised to generate sustainable market-beating returns and two that may face trouble.

Two healthcare stocks to sell:

Bruker (BRKR)

Market Cap: $8.77 billion

With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels.

Why Does BRKR Fall Short?

1. Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth

2. Incremental sales over the last five years were less profitable as its earnings per share were flat while its revenue grew

3. Diminishing returns on capital suggest its earlier profit pools are drying up

Bruker’s stock price of $57.59 implies a valuation ratio of 25.6x forward P/E. Read our free research report to see why you should think twice about including BRKR in your portfolio, it’s free.

Bio-Techne (TECH)

Market Cap: $11.38 billion

With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development.

Why Should You Sell TECH?

1. Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion

2. Modest revenue base of $1.22 billion gives it less fixed cost leverage and fewer distribution channels than larger companies

3. Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results

Bio-Techne is trading at $72.64 per share, or 35.3x forward P/E. To fully understand why you should be careful with TECH, check out our full research report (it’s free).